shutterstock_503973673_i_wei_huang
I Wei Huang / Shutterstock.com
26 May 2022EuropeLydia Birch

Neurim, Flynn discover that time is not on their side

In the third chapter of Neurim and Flynn’s dispute with generic companies, handed down on April 23, Mr Justice Mellor refused the claimants’ application for an interim injunction against generic giant, Teva, on the basis that Teva would not be adequately compensated by damages if its melatonin product was taken off the market.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
26 March 2026   LSIPR sister title launches vetted list celebrating leading in-house counsel who demonstrate exceptional ability in managing their organisation's IP portfolio, legal team, and IP culture.
Europe
24 March 2026   The drugmaker’s attempt to extend protection for a fast-growing oestrogen-free contraceptive ran into a landmark EU ruling, with the court not persuaded to read it narrowly.
Europe
24 March 2026   The European Patent Office’s Technology Dashboard reveals only a slight increase in medtech filings, and drops in biotech and pharma, against an overall healthy backdrop.